Research: There are few effective treatments that prevent oncogenic activities of mutant p53 protein, a major suppressor of cancer. Prives’ research will focus on a novel mechanism by which Mdm2 degrades p53, a series of CRISPR-derived cell lines harboring Li-Fraumeni-Syndrome p53 mutations, p53- independent roles of Mdm2 and MdmX, long non-coding RNAs that are p53 targets, new approaches to understand how p53 identifies its sites in vitro and in vivo and examination at single molecule resolution the localization of wild-type and mutant forms of p53 and Mdm2 after different stimuli. This will help diagnosis and treatment of sporadic and inherited cancers.
